As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Addex Therapeutics Ltd. The largest reported stake is Timothy Mark Dyer's, at 9.01%. 2 filings are on record since August 27, 2026 (Schedule 13D/A, September 4, 2026).
Sell to companies like Addex Therapeutics Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Addex Therapeutics Ltd. has 2 Schedule 13D or 13G filings on record since 2026-08-27. 1 holder's latest filing reports 5% or more of american depositary shares, each representing 120 ordinary shares ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.01% | 19,165,714 | SCHEDULE 13D/A, 2026-09-04 | 2026-09-02 |
Holding shares or following this stake? See who's behind Addex Therapeutics Ltd. and the warning signs.
Free to see. No signup.
Watch Addex Therapeutics Ltd.
Get an email when Addex Therapeutics Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Addex Therapeutics Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Addex Therapeutics Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Addex Therapeutics Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Timothy Mark Dyer | 19,165,714 | 0 | 19,165,714 | 0 | SCHEDULE 13D/A, 2026-09-04 |
The latest filing identifies Addex Therapeutics Ltd. by CUSIP 00654J206 and gives its principal executive office as Chemin des Mines 9, Geneva (SCHEDULE 13D/A, 2026-09-04).
Source of funds (Item 3)
Reporting Person is deemed to beneficially own 19,165,714 Shares of the Issuer as reflected in this Schedule 13D. Prior to May 21, 2007, Reporting Person acquired 7,811 founder shares at a purchase price of CHF1.00. The source of funds for such purchase was Reporting Person's personal funds. On August 9, 2013, Reporting Person acquired 36,364 Shares at a purchase price of CHF2.75 per share through participation in a private placement. The source of funds for such purchase was Reporting Person's personal funds.Timothy Mark Dyer, SCHEDULE 13D/A, 2026-09-04
Purpose of Transaction (Item 4)
Timothy Mark Dyer
The Reporting Person acquired the securities of the Issuer at founding, through the exercise of options, acquisitions through participation in private placements and in consideration for his services as Chief Executive Officer of the Issuer. The reporting person also received shares issuable upon exercise of options. The terms of the Reporting Person's employment arrangements for 2025 were set forth in the Issuer's Annual Report on Form 20-F for such period filed by the Issuer with the Securities and Exchange Commission on May 15, 2026. Except in respect of such employment arrangements as set forth therein, the Reporting Person does not have any present plans which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-04; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-08-27 | Timothy Mark Dyer | 8.98% | SCHEDULE 13D/A |
| 2026-09-04 | Timothy Mark Dyer | 9.01% | SCHEDULE 13D/A |
Questions about who owns Addex Therapeutics Ltd.
Who owns Addex Therapeutics Ltd.?
On this page, one holder's latest ownership filing reports 5% or more of Addex Therapeutics Ltd.: Timothy Mark Dyer (9.01%, Schedule 13D/A, filed 2026-09-04).
When did Timothy Mark Dyer buy into Addex Therapeutics Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Timothy Mark Dyer on this page is the Schedule 13D/A, filed 2026-08-27, reporting 8.98%; its latest, Schedule 13D/A filed 2026-09-04, reports 9.01%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Addex Therapeutics Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.